It has been more than 10 years since the pivotal trial E1684 first showed improvement in overall survival (OS) for melanoma patients treated with adjuvant high-dose interferon (HDI) [1], but controversies continue regarding the use of interferon (IFN) as adjuvant therapy in melanoma patients. Here, IFNA1 is linked to melanoma.